Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs McKesson Corporation — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $13.28, while McKesson Corporation trades at $823.62 (market cap $97.35B). The key difference: McKesson Corporation pays a 0.39% dividend while KraneShares Hang Seng TECH Index ETF pays none, and McKesson Corporation is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| KTEC | MCK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $19.51 | $995.69 |
52-Week Low | $12.00 | $659.01 |
Market Cap | — | $97.35B |
Enterprise Value | — | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC stock is trading at $13.28, up 2.23% today, showing positive momentum. The stock's technical picture indicates recent strength, though key financial ratios including P/E, P/S, and profitability metrics are currently unavailable for analysis. No recent earnings data or business developments are accessible to provide fundamental context.
Investment outlook remains unclear due to insufficient financial data. The primary opportunity lies in the stock's recent price appreciation, while risks include limited transparency on company fundamentals and the absence of analyst coverage or institutional positioning data to validate current valuation levels.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
